Acetyl-L-Carnitine (ALCAR) for Alzheimer's Disease
Also known as: ALCAR, ALC, Levacecarnine
ALCAR enhances acetylcholine synthesis and mitochondrial function — addressing two core deficits in Alzheimer's disease.
Mechanism of Action
ALCAR donates its acetyl group for acetylcholine synthesis, supporting the cholinergic system impaired in AD. It enhances mitochondrial function in hippocampal neurons, reduces amyloid-beta neurotoxicity, and promotes NGF receptor expression.
General mechanism: Acetylated amino acid derivative. Mitochondrial fatty acid transport, acetyl group donor for acetylcholine synthesis, neurotrophic factor enhancer.
Current Evidence
Meta-analysis of clinical trials shows mild benefit in early-onset AD and MCI. Effects more pronounced in younger patients and early disease stages.
Clinical Status: Multiple Phase II/III trials. Meta-analysis supports mild efficacy in early-stage AD.
Safety Profile
Very safe. GI effects possible. May increase seizure frequency in susceptible individuals. Fishy body odor at high doses.
Key Research Questions
- Is ALCAR more effective in early-onset vs late-onset Alzheimer's?
- Can ALCAR combined with donepezil provide additive cholinergic support?